Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: Zeev Hed who wrote (24599)	1/25/2002 11:30:21 AM
From: Sully-	Read Replies (2) \| Respond to of 99280

11:27 ET Imclone Sys (IMCL) 15.80 -3.78 (-19.3%): -- Update -- Issue downgraded at Gruntal following a series of negative SEC filings, including one disclosing the involuntary sell of stk by mgmt that was pledged as collateral to cover margin loans made to the officers by two large banks. Firm's intermediate-term rating was cut to Mkt Perform from Mkt Outperform. 11:16 ET Looksmart Ltd (LOOK) 1.90 +0.36 (+23.4%): Shares of Internet search co experiencing extremely heavy turnover this morning. Issue has already traded 3.28 mln shares on the session, or approx. 10x avg daily turnover. Unable to find news that would explain the surge in volume.

To: Zeev Hed who wrote (24599)	1/25/2002 11:40:15 AM
From: hotlinktuna	Respond to of 99280

Zeev...got back in CYBX 11.98 last 12.18 +.28 on this news: Friday January 25, 8:30 am Eastern Time Press Release SOURCE: Cyberonics, Inc. Cyberonics Q3 Conference Call Scheduled for February 6, 2002 Q3 Worldwide Sales to Exceed $18 Million; Q3 U.S. Sales to Exceed $16.7 Million; Q3 U.S. Annual Sales Growth to Exceed 40%; Encouraging Preliminary Long-Term Depression Pivotal Study Results HOUSTON, Jan. 25 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX - news) today announced that for the third quarter ending January 25, 2002, record worldwide sales of Cyberonics' NeuroCybernetic Prosthesis (NCP®) System will exceed $18 million and record U.S. sales will exceed $16.7 million. Annual U.S. sales growth in Q3 will exceed 40% compared to annual U.S. sales growth of 20% in Q2 and 11% in Q1. ``We started and are finishing Q3 ahead of plan, just as we did in the prior two quarters of fiscal 2002,'' commented Pamela B. Westbrook, Vice President of Finance and Administration and Chief Financial Officer. ``We expect that Q3 epilepsy profitability and our consolidated net loss will be favorably impacted by the record Q3 sales results. We are looking forward to presenting our complete Q3 results and an updated look at the depression pivotal study data on February 6, 2002.'' Richard L. Rudolph, M.D., Cyberonics' Vice President of Clinical and Medical Affairs and Chief Medical Officer added, ``The more depression pivotal study data we and the investigators review, the more encouraged we are that this is the case of a failed acute study, not a failed therapy. In the 60-patient depression pilot study, response rates increased from 31% at the end of the 12-week acute study to 45% after one year of VNS Therapy(TM). Although the patients in the pivotal study treatment group were receiving lower acute doses of stimulation than the patients in the pilot study, we are so far seeing similar preliminary long-term response rates in the pivotal study. The pivotal study placebo group response rate after three months of placebo was 10%, the response rate on all 232 pivotal study patients with three months of VNS Therapy is 19%, the response rate on 40% of the pivotal study patients with 9 months of VNS Therapy is 36% and the response rate on 15% of the patients with one year of VNS Therapy is 44%. These sustained and improving long-term response rates in patients with this level of chronic, recurrent and treatment-resistant depression are without precedent.'' Dr. Rudolph continued, ``We are continuing to review all aspects of the depression pivotal study including long-term data, acute and long-term stimulation parameters, dose responses, patient medical histories, results by study site and the blinded ratings videos. We expect to complete our thorough review in March and move forward with a revised depression clinical development and regulatory plan immediately thereafter.'' February 6, 2002 Conference Call The Company has scheduled a simultaneous conference call and internet presentation to discuss final Q3 results for 4:30 PM EST on Wednesday, February 6, 2002. Two separate phone lines are necessary to access the conference call and Internet presentation. The audio portion of the conference call may be accessed by dialing 877-451-8943 (if dialing from within the U.S.) or 706-679-3062 (if dialing from outside the U.S.). The conference ID is 3066392; the leader is Pam Westbrook. A replay